Aethlon Medical Announces Compliance With Nasdaq Listing Criteria

Tuesday, October 10, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

SAN DIEGO, Oct. 10, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a therapeutic technology company focused on

unmet needs in global health and biodefense, today announced that Nasdaq has formally notified the Company that it has demonstrated compliance with all applicable requirements for the continued listing of its common stock on The Nasdaq Capital Market,
including the $2.5 million stockholders' equity requirement. As previously disclosed, the Nasdaq Hearings Panel required the Company to evidence compliance with the stockholders' equity requirement by October 31, 2017. As a result of the foregoing, the Nasdaq compliance matter has been closed.

About Aethlon Medical

Aethlon Medical is focused on addressing unmet needs in global health and biodefense. The Aethlon HemopurifierŪ is a first-in-class therapeutic device designed to address life-threatening viral infections.  The United States Food and Drug Administration (FDA) has designated the HemopurifierŪ to an Expedited Access Pathway (EAP) related to the treatment of life-threatening viruses that are not addressed with approved therapies.

In collaboration with leading government and non-government research institutes, Aethlon has validated the ability of the HemopurifierŪ to capture a broad-spectrum of pandemic influenza viruses, mosquito-borne viruses and deadly hemorrhagic viruses.  Based on its use to treat Ebola virus, the HemopurifierŪ was named a "Top 25 Invention" and one of the "Eleven Most Remarkable Advances in Healthcare," by TIME Magazine.

Aethlon is also investigating the potential therapeutic use of the HemopurifierŪ to reduce the presence of tumor-derived exosomes, which contribute to immune-suppression and the spread of metastasis in cancer patients.  Additionally, Aethlon is the majority owner of Exosome Sciences, Inc. (ESI), which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disorders, including Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy (CTE).  Additional information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com.  You can also connect with us on Twitter, LinkedIn, Facebook and Google+.

Company Contact:Jim FrakesChief Financial OfficerAethlon Medical, Inc. 858-459-7800 [email protected]

Investor Relations:John MarcoCORE IR516 222 [email protected]

 

View original content:http://www.prnewswire.com/news-releases/aethlon-medical-announces-compliance-with-nasdaq-listing-criteria-300534099.html

SOURCE Aethlon Medical, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook